Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection

Leukemia and Lymphoma

Volumn 51, Issue 11, 2010, Pages 2063-2069

  Xicoy, Blanca ^a   Ribera, Josep Maria ^a   Mate, José Lus ^a   Tapia, Gustavo ^a   Morgades, Mireia ^a   Navarro, José Toms ^a   Sanz, Carolina ^a   Ariza, Aurelio ^a   Feliu, Evarist ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

HIV related non Hodgkin lymphoma; prognosis; tissue microarray

Indexed keywords

ANTIRETROVIRUS AGENT; BCL2 RELATED PROTEIN A1; BLEOMYCIN; CD103 ANTIGEN; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; SYNDECAN 1; VINCRISTINE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GERMINAL CENTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GERMINAL CENTER; HIV INFECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METABOLOME; MIDDLE AGED; PROGNOSIS; TISSUE ARRAY ANALYSIS;

EID: 78649279717     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.520772     Document Type: Article

References (54)

1. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995-1007.
2. Shipp MA, Ross KN, Weng AP, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
3. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2002;98:945-951.
4. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large B-cell expression of six genes. N Engl J Med 2004;350:1828-1837.
5. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
6. Alizadeh AA, Gentles AJ, Lossos IS, Levy R. Molecular outcome prediction in diffuse large-B cell lymphoma. N Engl J Med 2009;360:2794-2795.
7. Dunphy CH. Gene expression profiling data in lymphoma and leukaemia. Arch Pathol Lab Med 2006;130:483-520.
8. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B cell lymphoma. N Engl J Med 2002;346:1937-1947.
9. Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse-large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805-812.
10. De Paepe P, De Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 2007;21:37-43.
11. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136-1143.
12. Haarer CF, Roberts RA, Frutiger YM, Grogan TM, Rimsza LM. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med 2006;130:1819-1824.
13. Alacacioglu I, Ozcan MA, Ozkal S, et al. Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma. Hematology 2009;14:84-89.
14. Al-Kuraya KS, Siraj AK, Al-Dayel FA, et al. Epigenetic changes and their clinical relevance in Saudi diffuse large B-cell lymphoma. A molecular and tissue microarray analysis of 100 cases. Saudi Med J 2005;26:1099-1103.
15. Zinzani PL, Dirnhofer S, Sabattini E, et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica 2005;90:341-347.
16. Carbone A, Gaidano G, Gloghini A, et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndromerelated non-Hodgkin's lymphomas. Blood 1998;91:747-755.
17. Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse-large B-cell lymphoma. Am J Surg Pathol 2004;28:464-470.
18. Hans CP, Wesenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
19. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
20. Colomo L, López-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78-84.
21. Zinzani PL, Dimhofer S, Sabattini E, et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumours with nodal presentation on tissue microarrays. Haematologica 2005;90:341-347.
22. Tirelli U, Spina M, Gaidano G, Vaccher E, Franceschi S, Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS 2000;14:1675-1688.
23. Kirk O, Pedersen C, Cozzi-Lepri A, et al.; EuroSIDA Study Group. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406-3412.
24. Carbone A. AIDS-related non-Hodgkin's subsets of human immunodeficiency virus-related lymphomas. Blood 2001;97:744-751.
25. Carbone A, Dolcetti R, Gloghini A. Immunophenotypic and molecular analyses of acquired immune deficiency syndromerelated and Epstein-Barr virus-associated lymphomas: a comparative study. Hum Pathol 1996;27:133-146.
26. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM/IFR4, BCL-6 and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001;97:744-751.
27. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1-18.
28. Miralles P, Rubio C, Berenguer J, et al. Recomendaciones de GESIDA/Plan Nacional sobre el Sida sobre el diagnóstico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana. Med Clin (Barc) 2002;118:225-236.
29. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. J Clin Oncol 1999;17:3835-3849.
30. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. The International Harmonization Project on Lymphoma. J Clin Oncol 2007;25:579-586.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
32. 2/E in the log-rank test for survival data or tumor incidence data. Biometrics 1973;29:579-584.
33. Cox DR. Regression models and life tables. J R Stat Soc 1972;3:187-200.
34. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004;104:2933-2935.
35. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. Clin Oncol 2006;24:961-968.
36. Linderoth J, Ehinger M, Akerman M, et al. Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. Eur J Haematol 2007;79:146-149.
37. Obermann EC, Went P, Zimpfer A, et al. Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis. BMC Cancer 2005;5:162.
38. Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol 2005;32:227-234.
39. Ramuz O, Bouabdallah R, Devilard E, et al. Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas. Int J Oncol 2005;26:151-157.
40. Went P, Dellas T, Bourgau C, et al. Expression profile and prognostic significance of CD24, p53 and p21 in lymphomas. A tissue microarray study of over 600 non-Hodgkin lymphomas. Dtsch Med Wochenschr 2004;129:2094-2099.
41. Tzankov A, Pehrs AC, Zimpfer A, et al. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol 2003;56:747-752.
42. Lee NR, Song EK, Jang KY, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008;49:247-256.
43. Van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24:4135-4142.
44. Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active antiretroviral therapy (HAART) on response to treatment and survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. Br J Haematol 2001;112:909-915.
45. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-1491.
46. Navarro JT, Ribera JM, Oriol A, et al. Favorable impact of virological response to HAART on survival in patients with AIDS-related lymphoma. Leuk Lymphoma 2002;43:1837-1842.
47. Ilić I, Mitrović Z, Aurer I, et al. Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol 2009;90:74-80.
48. Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009;100:1842-1847.
49. Wilson KS, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:1002-1009.
50. Leroy K, Jais JP, Haioun C, et al. Gene expression profile associated with survival in patients with diffuse-large B-cell lymphoma treated by chemotherapy and rituximab. Blood 2005;106(Suppl. 1):Abstract 159.
51. Hoffmann C, Tiemann M, Schrader C, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 2005;106:1762-1769.
52. Copie-Bergman C, Gaulard P, Leroy K, et al. Immunofluorescence in situ hybridization index predicts survival in patients with diffuse-large B cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 2009;27:5573-5579.
53. Chadburn A, Chen X, Chiu A, et al. Neither germinal center (GC) vs non-germinal center (non-GC) phenotype nor FOXP1 expression correlate with outcome in AIDS-associated diffuse-large B-cell lymphoma (DLBCL): study of patients from AIDS Malignancies Consortium Ttrials 010 and 034. Blood 2006;108(Suppl. 1):Abstract 2023.
54. Chadburn A, Chiu A, Lee JY, et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol 2009;27:5039-5048.